Agenda

ADDF Summit 2024

The full-day symposium will be broken into a morning and afternoon session that features a keynote, presentations by ADDF-funded investigators, and two panels convening industry experts. All rooms are on the ground floor of the hotel.
‍
‍Breakfast and lunch will be served. Coffee and refreshments will be available throughout the day.

All Sessions

Morning Session

Exploring Novel Approaches: Emerging Therapeutics Guided by the Biology of Aging

8:00 –

8:30 am

Breakfast

Bristol

8:30 –

8:45 am

Opening Remarks

Mark Roithmayr (ADDF)

Howard Fillit, MD (ADDF)

‍

8:45 –

9:00 am

Overview of the ADDF Portfolio

Laura Nisenbaum, PhD (ADDF)

9:00 -

9:05 am

Overview of Morning Session

Aaron Burstein, PharmD, FCCP (ADDF)

‍

9:05 -

9:25 am

SPECTRIS Treatment of Alzheimer’s Disease

Londres

Ralph Kern, MD, MHSc (Cognito Therapeutics)

9:25 -

9:45 am

GliaPharm's Lead Candidate to Rescue Hypometabolism in Alzheimer's Disease

Londres

Charles Finsterwald, PhD (GliaPharm)

9:45 -

10:05 am

Break

Londres Foyer

10:05 -

11:10 am

Future of Alzheimer’s Biomarkers in Clinical Care and Research

Moderator: Miia Kivipelto, MD, PhD (Karolinska Institutet)

Panelists:

Joel Braunstein, MD (C2N)

Jeffrey Cummings, MD, ScD (University of Nevada, Las Vegas)

Suzanne Schindler, MD, PhD (Washington University)

Charlotte Teunissen, PhD (Amsterdam UMC)

Henrik Zetterberg, MD, PhD (University of Gothenberg)

Howard Fillit, MD (ADDF)

11:10 -

11:40 am

Keynote: Biomarker Observatory

Jeffrey Cummings, MD, ScD (University of Nevada, Las Vegas)

11:40 -

12:15 pm

Keynote Q&A

Jeffrey Cummings, MD, ScD (University of Nevada, Las Vegas)

Howard Fillit, MD (ADDF)

Afternoon Session

Harnessing the Power of Combination Therapies: Drug Repurposing, Biologics, and Beyond in Alzheimer’s Research

12:15 -

1:15 pm

Lunch

Bristol

1:15 -

1:20 pm

Overview of Afternoon Session

Aaron Burstein, PharmD, FCCP (ADDF)

1:20 -

1:40 pm

Advancements in Gerotherapeutics for the Prevention and Treatment of Alzheimer’s Disease

Miranda Orr, PhD (Wake Forest University)

1:40 -

2:00 pm

Combination Biologics: The Next Generation of Therapeutics for Neurodegeneration

Howard Berman, PhD (Coya Therapeutics)

Stanley Appel, MD (Coya Therapeutics)

2:00 -

2:20 pm

Portfolio Presentation #5

Miia Kivipelto, MD, PhD (Karolinska Institutet)

2:20 -

2:40 pm

Break

Londres Foyer

2:40 -

3:45 pm

Opportunities and Challenges for Combination Therapy Clinical Trials in Alzheimer’s Disease

Moderator: Philip Scheltens, MD, PhD (EQT Life Sciences)

Panelists:

Georgia Frost, PhD (Dementia Discovery Fund)

Susan Kohlhaas, PhD (Alzheimer's Research UK)

Eric McDade, DO (Washington University)

Miranda Orr, PhD (Wake Forest University)

Howard Fillit, MD (ADDF)

3:45 -

3:55 pm

Wrap Up

Mark Roithmayr (ADDF)

3:55 -

5:00 pm

Networking Reception

Oxford

Morning Session

8:00 –

8:30 am

Breakfast

Bristol

8:30 –

8:45 am

Opening Remarks

Mark Roithmayr (ADDF)

Howard Fillit, MD (ADDF)

‍

8:45 –

9:00 am

Overview of the ADDF Portfolio

Laura Nisenbaum, PhD (ADDF)

9:00 -

9:05 am

Overview of Morning Session

Aaron Burstein, PharmD, FCCP (ADDF)

‍

9:05 -

9:25 am

SPECTRIS Treatment of Alzheimer’s Disease

Londres

Ralph Kern, MD, MHSc (Cognito Therapeutics)

9:25 -

9:45 am

GliaPharm's Lead Candidate to Rescue Hypometabolism in Alzheimer's Disease

Londres

Charles Finsterwald, PhD (GliaPharm)

9:45 -

10:05 am

Break

Londres Foyer

10:05 -

11:10 am

Future of Alzheimer’s Biomarkers in Clinical Care and Research

Moderator: Miia Kivipelto, MD, PhD (Karolinska Institutet)

Panelists:

Joel Braunstein, MD (C2N)

Jeffrey Cummings, MD, ScD (University of Nevada, Las Vegas)

Suzanne Schindler, MD, PhD (Washington University)

Charlotte Teunissen, PhD (Amsterdam UMC)

Henrik Zetterberg, MD, PhD (University of Gothenberg)

Howard Fillit, MD (ADDF)

11:10 -

11:40 am

Keynote: Biomarker Observatory

Jeffrey Cummings, MD, ScD (University of Nevada, Las Vegas)

11:40 -

12:15 pm

Keynote Q&A

Jeffrey Cummings, MD, ScD (University of Nevada, Las Vegas)

Howard Fillit, MD (ADDF)

Afternoon Session

12:15 -

1:15 pm

Lunch

Bristol

1:15 -

1:20 pm

Overview of Afternoon Session

Aaron Burstein, PharmD, FCCP (ADDF)

1:20 -

1:40 pm

Advancements in Gerotherapeutics for the Prevention and Treatment of Alzheimer’s Disease

Miranda Orr, PhD (Wake Forest University)

1:40 -

2:00 pm

Combination Biologics: The Next Generation of Therapeutics for Neurodegeneration

Howard Berman, PhD (Coya Therapeutics)

Stanley Appel, MD (Coya Therapeutics)

2:00 -

2:20 pm

Portfolio Presentation #5

Miia Kivipelto, MD, PhD (Karolinska Institutet)

2:20 -

2:40 pm

Break

Londres Foyer

2:40 -

3:45 pm

Opportunities and Challenges for Combination Therapy Clinical Trials in Alzheimer’s Disease

Moderator: Philip Scheltens, MD, PhD (EQT Life Sciences)

Panelists:

Georgia Frost, PhD (Dementia Discovery Fund)

Susan Kohlhaas, PhD (Alzheimer's Research UK)

Eric McDade, DO (Washington University)

Miranda Orr, PhD (Wake Forest University)

Howard Fillit, MD (ADDF)

3:45 -

3:55 pm

Wrap Up

Mark Roithmayr (ADDF)

3:55 -

5:00 pm

Networking Reception

Oxford